Special Issue "Histoplasma and Histoplasmosis 2020"
Deadline for manuscript submissions: closed (15 May 2021) | Viewed by 13598
Interests: histoplasma and histoplasmosis; TB meningitis; cryptococcal meningitis; diagnostic testing; opportunistic infections
Interests: HIV infectious diseases; malaria; AIDS; Plasmodium; Falciparum malaria; Vivax malaria
Special Issues, Collections and Topics in MDPI journals
Histoplasmosis is often described as having a narrow endemic area. The era of HIV and the ever increasing use of immune suppressive medications have shown us that this way of thinking isn’t accurate. In fact, though histoplasmosis is certainly more frequent in certain areas of the world, the disease has been detected nearly worldwide. In Latin America, it is the most frequent cause of mortality among those with advanced HIV but is frequently mis-diagnosed as ‘culture-negative’ tuberculosis. In much of the world, the lack of readily available rapid diagnostic tests is a major barrier to diagnosis of histoplasmosis. Diagnostic difficulties aside, therapeutics are also problematic. Liposomal amphotericin b is mostly unavailable for severe presentations. Itraconazole is the treatment of choice in many situations but can be difficult for patients to tolerate and is frequently implicated in drug interactions.
Are there better treatments and are any of the new antifungal medications candidates to improve treatment tolerability? Why are we missing so many cases and is it really as straightforward as needing better diagnostic tests? What actual progress has been made in reducing the burden of disease worldwide? Can we prevent histoplasmosis? Why do the seemingly rare immunologic manifestations of histoplasmosis occur?
This Special Issue of the Journal of Fungi will seek to answer some basic and important questions about histoplasmosis to which the answers are not yet known in hopes of increasing our knowledge of the disease and making progress towards decreasing the worldwide burden.
Dr. Nathan C. Bahr
Prof. Dr. Mathieu Nacher
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Fungi is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- endemic fungi
- opportunistic infections
- fungal epidemiology